Cyclin D1 is necessary for the efficient development of EVI1-AML in vivo. (A) Relative cell proliferation of EVI1-AML cells expressing shRNAs against Luciferase and Ccnd1 in vitro. The data for shLuciferase are common to those in Figure 4A. (B) Colony-forming units of EVI1-AML cells expressing shRNAs against Luciferase and Ccnd1. The data for shLuciferase are common to those in Figure 4B. (C) Relative cell proliferation of KMT2A-MLLT1 CL2 cells expressing shRNAs against Luciferase and Ccnd1 in vitro. The data for shLuciferase are common to Figure 4E. (D) Colony-forming units of KMT2A-MLLT1 CL2 cells expressing shRNAs against Luciferase and Ccnd1. The data for shLuciferase are common to Figure 4F. (E) Frequency of GFP⁺ AML cells in the peripheral blood in recipient mice that underwent transplantation with EVI1-AML cells expressing indicated shRNAs. (F) A Kaplan-Meier survival curve for recipient mice that underwent transplantation with 1 × 10⁶ EVI1-AML cells expressing shRNAs against Luciferase and Ccnd1, after being exposed to 6.5 Gy TBI. P value was examined by a log-rank test. The data for shLuciferase are common to Figure 4C. (G) A Kaplan-Meier survival curve for recipient mice that underwent transplantation with 1 × 10⁴ KMT2A-MLLT1-AML cells expressing shRNAs against Luciferase and Ccnd1, after being exposed to 6.5 Gy TBI. P value was examined by a log-rank test. The data for shLuciferase are common to Figure 4H. Mean ± SD. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001.